Dulaglutide
Published date: 2026-05-22 11:36:30
|
Name | Dulaglutide | CAS# | 923950-08-7 |
|---|---|---|---|---|
| Price | $242.63/10mg $4872.6/1g | Purity | 99.71% | |
| Stocking Period |
3 Day | Stock | In Stock | |
| Product Webpage: | http://www.zhaokebio.com | |||
| Detail
Product Information
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist consisting of a GLP-1 analog covalently linked to a modified human immunoglobulin G4 (IgG4) Fc fragment. It is approved for the treatment of type 2 diabetes mellitus (T2DM) as a once-weekly subcutaneous injection, offering sustained glycemic control with reduced dosing frequency compared to daily GLP-1 agonists. Product Highlights: Once-Weekly Dosing: Fusion to human IgG4-Fc extends half-life to ~5 days via FcRn recycling, enabling convenient once-weekly subcutaneous administration. Superior patient adherence compared to daily GLP-1 injections; strong competitive positioning in the T2DM market. Cardiovascular Benefits: Demonstrated reduction in major adverse cardiovascular events (MACE) in the REWIND trial - 12% relative risk reduction versus placebo. Cardioprotective profile supports premium pricing and broad formulary inclusion in diabetes management protocols. Fusion Protein Design: Novel GLP-1-IgG4 Fc fusion construct provides exceptional metabolic stability and reduced immunogenicity compared to pegylated alternatives. Proven biologic platform technology with established manufacturing processes and regulatory pathway. Weight Loss Efficacy: Clinically meaningful weight reduction (average 3-4.5 kg) alongside glycemic control, addressing dual metabolic goals. Growing demand from the intersection of diabetes and obesity therapeutics with expanding label potential. |